P633: UPDATED SAFETY AND EFFICACY RESULTS OF ZANUBRUTINIB IN PATIENTS WITH B-CELL MALIGNANCIES WHO ARE INTOLERANT OF IBRUTINIB AND/OR ACALABRUTINIB

• Mazyar Shadman,
• Moshe Y. Levy,
• Ryan Porter,
• John M. Burke,
• Jennifer L. Cultrera,
• Jamal Misleh,
• Jeff Sharman,
• Syed F. Zafar,
• Kunthel By,
• Aileen Cohen,
• Rocco Crescenzo,
• Adam Idoine,
• Ian W. Flinn

Affiliations

Mazyar Shadman

1 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, United States

Moshe Y. Levy

2 Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, United States

Ryan Porter

3 SSM Health Dean Medical Group, Madison, United States

John M. Burke

4 Rocky Mountain Cancer Centers, Aurora, United States

Jennifer L. Cultrera

5 Florida Cancer Specialists and Research Institute, Leesburg, United States

Jamal Misleh

6 Medical Oncology Hematology Consultants PA, Newark, United States

Jeff Sharman

7 Willamette Valley Cancer Institute and Research Center, Eugene, United States

Syed F. Zafar

8 Florida Cancer Specialists and Research Institute, Fort Myers, United States

Kunthel By

9 BeiGene USA, Inc., San Mateo, United States

Aileen Cohen

9 BeiGene USA, Inc., San Mateo, United States

Rocco Crescenzo

9 BeiGene USA, Inc., San Mateo, United States

Adam Idoine

9 BeiGene USA, Inc., San Mateo, United States

Ian W. Flinn

10 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, United States